- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07856797
A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds (Radiesse China)
A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds
The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Public Disclosure Manager
- Numéro de téléphone: +1 984-301-3095
- E-mail: Aesthetic.Trials@merz.com
Lieux d'étude
-
-
-
Beijing, Chine, 100034
- Recrutement
- Merz Investigative Site
-
Changde, Chine, 415000
- Recrutement
- Merz Investigative Site
-
Chengdu, Chine, 610021
- Recrutement
- Merz Investigative Site
-
Gaozhou, Chine, 525200
- Recrutement
- Merz Investigative Site
-
Hangzhou, Chine, 311200
- Recrutement
- Merz Investigative Site
-
Nanjing, Chine, 210029
- Recrutement
- Merz Investigative Site
-
Xianyang, Chine, 712099
- Recrutement
- Merz Investigative Site
-
Yibin, Chine, 644000
- Recrutement
- Merz Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- WSRS score of 3 (moderate) or 4 (severe) in both right and left NLFs, as determined live by the treating investigator. The WSRS score for the right and the left NLF does not have to be equal.
- Willing to abstain from other aesthetic treatments in the NLF area during study participation.
Exclusion Criteria:
- Prior dermal filler or implant material detectable in the NLF area by ultrasound.
- Active infection or acute inflammation at treatment sites.
- Hyaluronic Acid or collagen filler treatment in NLFs within 12 months.
- CaHA or Poly L-Lactic Acid filler treatment in NLFs within 24 months.
- Recent facial dermal therapies in the midface region within the past 6 months.
- Prior facial surgery or implants that could interfere with assessments.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RADIESSE® Injectable Implant
Participants will receive a single injection of RADIESSE® administered to both NLFs on Day 1. Participants may receive an optional touch-up injection at Month 1 following the initial treatment at investigator's discretion. RADIESSE® will be administered according to the current product labelling and instruction for use. |
Participants will receive treatment with RADIESSE® Injectable Implant.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Achieving at Least a 1-point Improvement in Both NLFs From Baseline to Month 6 after Last Treatment on the Wrinkle Severity Rating Scale (WSRS), as Assessed Live by the Treating Investigator
Délai: At Month 6 after last treatment
|
Severity of the NLFs was assessed and measured using the 5-point WSRS, where 1=absent and 5=extreme. A lower score indicates better outcome. |
At Month 6 after last treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Investigator Global Aesthetic Improvement Scale (iGAIS) at Month 6 After Last Treatment, as Assessed Live by the Treating Investigator
Délai: At Month 6 after last treatment
|
The iGAIS is an assessment grading scale where the treating investigator describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). The investigator will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of the participants NLFs due to treatment, compared to the pretreatment photograph". Improvement is defined as a rating of +1, +2, or +3. The higher the iGAIS score, the greater the improvement. |
At Month 6 after last treatment
|
|
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Participant Global Aesthetic Improvement Scale (pGAIS) at Month 6 After Last Treatment, as Assessed Live by Participant
Délai: At Month 6 after last treatment
|
The pGAIS is a self-assessment grading scale where the participant independently describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). Participants will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of your NLFs due to treatment, compared to the pretreatment photograph?" Improvement is defined as a rating of +1, +2, or +3. The higher the pGAIS score, the greater the improvement. |
At Month 6 after last treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Merz Medical Expert, Merz North America, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- RAD-NLF-CN003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .